WRAL Tech Wire

Regenerative health startup Humacyte names Schering-Plough exec as CEO

Humacyte

On The Web

• Humacyte
• WRAL Tech Wire at Twitter - sign up today for latest news alerts

Site Search

Local Tech Wire

RESEARCH TRIANGLE PARK, N.C. – Carrie Cox, a veteran life science executive who was president of global pharmaceuticals at Schering-Plough, will be the new chief executive officer at regenerative health startup Humacyte.

Cox will assume the role and also join the Humacyte post on Sept. 20.

Humacyte, which launched in 2004, is a spinout from Duke University.

"We are clearly delighted to have an executive with the experience, leadership and sound business judgment of Carrie Cox to lead Humacyte at this important juncture in our company's history,” said Humacyte founder Laura Niklason. “Carrie is ideally qualified to oversee our ongoing product development efforts and lead us into commercialization of these much-needed treatment options for patients."

Cox worked at Schering-Plough from 2003 through November of last year. The company merged with Merck.

Over 30-year career, Cox also worked at Pharmacia.

Named six times to Fortune Magazine’s “50 Most Powerful Women in Business” list, Cox serves on the board at Texas Instruments, Cardinal Health and Celgene.

"I am proud to join Humacyte and become part of creating the future of regenerative medicine," said Cox in a statement. "The break-through science being conducted at Humacyte may one day bring major benefits to patients, while also improving health outcomes and reducing costs."

Humacyte is focused on vascular disease as well as dermal tissue filling and repair. The company is developing human tissues that can be shaped into tubes, sheets and shapes similar to native tissue.

Get the latest news alerts: Follow LTW at Twitter.

Editor's Blog

The latest blog posts from our WRAL Tech Wire and WRAL editors. Read more articles…